ArticleEuropean journal of medical research2025
The role of serum and urıne neopterın levels on the determınatıon of acute cholecystıtıs severıty.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAcute cholecystitis (AC) is one of the most common causes of hospital admissions due to abdominal pain. Early diagnosis and prompt initiation of treatment positively impact morbidity and mortality in AC. The aim of our study was to determine serum and urine concentrations of additional biomarkers at different stages of the disease, beyond those currently used in acute cholecystitis severity staging, and to evaluate their potential inclusion as new staging parameters.
methodsThis study prospectively analyzed data from 63 patients diagnosed with acute cholecystitis and treated by the same surgical team in 2020. In patients with AC, WBC, CRP, and PCT values, as outlined in the TG18 guidelines, showed an increasing trend. These values are commonly used to determine disease stage.
resultsA correlated increase in these infectious parameters was observed as disease severity progressed. The mean S-NEO value in Stage 1-2 patients was 20.082 ± 9.517 nmol/L, while the mean U-NEO value was 3.46 ± 2.95 µmol/L. In Stage 3 patients, the mean S-NEO value was 40.92 ± 7.878 nmol/L, and the mean U-NEO value was 4.4 ± 2.42 µmol/L. The Mann-Whitney U test revealed a significant difference in S-NEO values between Stage 1-2 and Stage 3 groups (p < 0.001). However, no significant difference was observed between these groups in terms of U-NEO values (p = 0.18).
conclusionIn patients with acute cholecystitis, S-NEO and U-NEO levels can serve as complementary biomarkers alongside existing diagnostic and staging parameters. Particularly in staging severity, S-NEO levels may play a crucial role in early diagnosis and timely initiation of treatment, given their high specificity and sensitivity at defined cut-off values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.